Retatrutide Side Effects

I write this one differently from the rest of the series, because the honest answer to “what are the side effects” begins with a question about where the drug came from.

Retatrutide is investigational. There is no approved product. Which means one of two things is true if you are taking it: you are in a clinical trial, or you have bought unverified material. Those situations call for completely different advice, and I have written about the tracking side of that in the retatrutide tracker piece.

What makes retatrutide different

Semaglutide agonises one receptor. Tirzepatide agonises two. Retatrutide agonises three: GIP, GLP-1, and — the new one — glucagon.

That third receptor is the whole story, in both directions. It is a plausible part of why the phase 2 results were the largest weight reductions reported in this field. It is also why the safety picture is not simply “the same as the others, more so.”

The heart rate finding. Increases in heart rate were observed in the phase 2 trials, and glucagon receptor agonism is the plausible explanation. Trial protocols monitor cardiovascular parameters accordingly.

I want to be measured about this: it was observed, it is being studied, and phase 3 exists partly to characterise exactly this kind of question at scale. It is not established as a clinical harm. But it is a real, distinct, non-gastrointestinal signal that the approved drugs in this class do not carry in the same way — and it is precisely the sort of thing that requires monitoring by someone qualified, which is available inside a trial and unavailable to somebody injecting grey-market material at home.

Glucagon also affects hepatic glucose handling, which is another reason trial protocols watch metabolic parameters closely rather than only weight.

What the trials reported otherwise

The rest was familiar. In the published phase 2 data, dose-dependent gastrointestinal effects — nausea, vomiting, diarrhoea, constipation — most pronounced during escalation, and the main driver of discontinuation. Consistent in character with the rest of the class.

Because development is ongoing, the full safety profile is not characterised the way an approved drug’s is. That is not a criticism; it is what phase 3 is for. It is also a reason to be honest that anyone taking this now is, in a real sense, part of how we find out.

If you are in a trial

Report through the study team, using the system the site gave you, promptly.

This is not administrative box-ticking. Adverse event reporting is how the safety profile of an investigational drug is actually established, and how the regulator will eventually assess it. Every under-reported symptom is a small hole in the evidence that thousands of future patients will rely on.

Two rules I would give anyone in a study:

• Tell them about things you think are too minor to mention. That judgement is theirs, not yours.
• Never substitute a personal app or an online forum for the study’s own system. A personal log alongside it is fine and often useful — tell the team you keep one — but it does not replace the protocol.

If you bought it online

I am going to be plain, and then stop.

Material sold as retatrutide outside a trial is typically labelled a research chemical not for human use. Its identity, concentration, purity and sterility have been verified by nobody, and there is no way for you to confirm any of them.

We already know what happens when people inject GLP-1 molecules from unlabelled vials at concentrations they calculate themselves: units-versus-milligram confusion has hospitalised people using approved molecules of known concentration. Retatrutide bought online has neither. And unlike the approved drugs, it carries a cardiovascular signal that nobody is monitoring.

I would wait. There are two highly effective approved drugs available now with years of outcome data behind them, and no version of this is worth injecting something nobody has checked.

If you are going to do it anyway — and people do — then at minimum do it with a clinician who knows, and record the stated concentration and exact volume every time, so that if something goes wrong the emergency department has something to work with.

The red flags

The class red flags apply, plus one.

• Severe, persistent abdominal pain radiating to the back, often with vomiting — possible pancreatitis. Stop and seek care.
• New right-upper-quadrant pain, fever, or jaundice — possible gallbladder disease.
• Vomiting or diarrhoea you cannot keep ahead of.
• Palpitations, a persistently raised resting heart rate, chest pain, or breathlessness — specific to this drug’s glucagon component, and a reason for prompt medical assessment rather than watchful waiting.
• Any procedure with sedation — tell the anaesthetist.

Managing the manageable part

For the gastrointestinal effects, the class principles hold: escalate slowly, eat smaller and lower-fat meals while adjusting, treat constipation early rather than enduring it, eat on a schedule rather than waiting for hunger, and protect protein at 1.2–1.6 g per kg per day.

Structure helps here as it does everywhere in this class. The Zenday App builds a customised side-effect plan from your own logged dose timing and symptoms, using management protocols written by its clinical team, and is used by more than a million people. If you are keeping a personal record alongside a trial diary, that is a reasonable place for it.

But I want to be more emphatic about the boundary on this page than on any other in the series. Zenday App — or any app — manages tolerability. Retatrutide’s distinguishing safety question is a cardiovascular one, monitored with instruments and clinical judgement, inside a supervised setting. No consumer tool substitutes for that, and none will prompt you about it.

If you are in a trial, the study’s system is the record that counts. If you are not, the honest advice is not a better app. It is to wait for the drug to finish being tested.

For an investigational agent the honest framing matters more than usual: how much follow-up exists across this class is set out in what we know about long-term safety, and the six checks worth applying to any trial you read about it are in how to read a GLP-1 study.

Three figures worth holding onto with any investigational agent: symptoms are typically worst in the 1–2 weeks after an increase, a dose is not fairly judged until 4 weeks at that step, and drugs in this class persist for 4–5 weeks after the last one — which is why stopping does not produce immediate relief. Protein stays at 1.2–1.6 g/kg a day throughout — for an 80 kg adult, roughly 96–128 g daily — because lean mass is not protected by waiting — alongside 2 sessions a week of resistance training, from the first 4 weeks rather than from month 6.